Phase II trial of docetaxel (T), cisplatin (P) and fluorouracil (5-FU) in the treatment of metastatic penile cancer

Phase II trial of docetaxel (T), cisplatin (P) and fluorouracil (5-FU) in the treatment of metastatic penile cancer - TPF in penile cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002697

Enrollment

Registered

2009-11-01

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with metastatic penile cancer

Interventions

docetaxel, cisplatin and fluorouracil

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Pathologically confirmed penile squamous cell carcinoma 2) M1 disease 3) At least one measurable tumor lesion 4) ECOG PS 0-1 5) Age 18-75 6) Normal organ function 7) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Usage of experimental drugs 2) History of serious drug allergy or hypersensitivity with cisplatin or paclitaxel 3) Peripheral neuropathy 4) Ototoxicity 5) Uncontrolled infection 6) Double cancer 7) Coexisting severe medical conditions 8) Mental disease 9) Judged as inappropriate to participate this trial by investigators

Design outcomes

Primary

Measure	Time frame
Response rate, Toxicity	—

Secondary

Measure	Time frame
Progression free survival, Quality of life	—

Countries

Asia(except Japan)

Contacts

Public ContactYao Zhu

Fudan University Shanghai Cancer Center Department of Urology

mailzhuyao@163.com86-21-64175590

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026